2023 Guidance and Q3 Earnings

2023 full year outlook considerations to support modelling Vaccines turnover Increase around 20%, excluding pandemic adjuvant sales Shingrix to increase mid-teens % Arexvy between £0.9bn and £1.0bn Flu to decrease around 25 to 30% Meningitis to increase mid-teens % Established Vaccines to increase high single-digit % Turnover to adj. operating profit items COGS: to increase at a rate broadly aligned to turnover SG&A: to increase at a rate broadly aligned to turnover R&D: to increase at a rate slightly below turnover Royalties: around £900m GSK adj. operating profit is expected to increase between 13% and 15% The above items exclude the impact of COVID-19 solutions Specialty Medicines turnover Increase low double-digit % for Specialty Medicines, excluding Xevudy sales HIV to increase around 10% Oncology to increase low single-digit % Adj. operating profit to adj. EPS items Interest: between £650m to £700m Share of associates: negligible Tax rate: around 15% to 15.5% Non-controlling interest: ViiV is main ongoing NCI, with Q1 2022 'Other' NCI not repeating GSK adj. EPS is expected to increase between 17% and 20% General Medicines turnover Increase low to mid single-digit % COVID-19 solutions Not anticipating significant sales Expect this to reduce GSK turnover growth by approximately 8% and reduce adj. operating profit growth by 4% to 5% Dividend Expect 56.5p per share GSK All turnover and growth comments at CER. Adj. is abbreviation for Adjusted. All expectations and targets regarding future performance and the dividend should be read together with the "Guidance, assumptions and cautionary statements" on page 52 of our third quarter 2023 earnings release, page 2 of our third quarter 2023 results announcement and the cautionary statement slide included with this presentation. Tax rate expectation is based on enacted legislation and is reflective of the anticipated performance of the business and key assets. The tax rate could fluctuate in individual years due to the timings of settlements of open years with tax authorities, as we continuously bring our tax affairs up to date, or due to changes in legislation. Interest expectation assumes no significant adverse movements in interest rates. 30 30

View entire presentation